Potential role of type I interferons in the treatment of pituitary adenomas

Rev Endocr Metab Disord. 2009 Jun;10(2):125-33. doi: 10.1007/s11154-008-9083-3. Epub 2008 Jul 6.

Abstract

Cytokines, particularly those endowed with pro-inflammatory properties, are known to influence the release of anterior pituitary hormones by a direct and indirect action at the level of pituitary gland and hypothalamus. Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies underline the fact that type I IFNs are involved in the regulation of the immune-endocrine circuitry. Treatment with type I IFNs of patients affected by chronic viral hepatitis, multiple sclerosis and tumors influences the secretion of pituitary hormones. This article reviews the current knowledge about the effects of IFN-alpha and IFN-beta on hypothalamic-pituitary function and describes the potential role of type I IFNs in the treatment of pituitary adenomas.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Hypothalamo-Hypophyseal System / drug effects
  • Interferon Type I / pharmacology
  • Interferon Type I / therapeutic use*
  • Pituitary Neoplasms / drug therapy*
  • Pituitary Neoplasms / metabolism
  • Pituitary-Adrenal System / drug effects
  • Receptor, Interferon alpha-beta / metabolism

Substances

  • Antineoplastic Agents
  • Interferon Type I
  • Receptor, Interferon alpha-beta